Introduction {#s1}
============

Hematopoietic stem cell transplantation (HSCT) is crucial for treating pediatric patients with blood- or bone marrow-related malignant diseases; due to technical advances in HSCT, the number of survivors who have undergone HSCT has been increasing rapidly ([@r1],[@r2],[@r3]). Since HSCT involves a conditioning therapy with intensive chemotherapy and/or radiation, many survivors have been revealed to show long-term consequences resulting from the therapy ([@r3], [@r4]). These consequences seriously affect the quality of life of the patients, and are considered one of the major medical concerns of the therapy. Thus, pediatric malignant disease patients have been called childhood cancer survivors (CCS), and regular examinations of the physical and psychological conditions of these patients are recommended ([@r5]).

HSCT is a vital option as a curative therapy for not only pediatric malignancies, but also for non-malignant and other related pediatric disorders, such as immunodeficiency syndromes, hemophagocytic lymph histiocytosis (HLH), and storage-related diseases ([@r6]). Especially, HSCT is a standard approach for treating infants with notable immunodeficiency syndromes, since poor prognosis is likely without appropriate intervention ([@r7]). Alkylating agents are key drugs used in the conditioning regimens for HSCT; however, the long-term consequences of these treatments have not yet been fully documented.

In the present study, we aimed to clarify the clinical details of the long-term endocrinological consequences of HSCT for non-malignant pediatric diseases; this would provide valuable insights into planning HSCT procedures for children with non-malignant diseases.

Materials and Methods {#s2}
=====================

The present study was approved by the ethical committee of the Tokyo Medical and Dental University (TMDU).

From 1983 to 2014, 153 patients had undergone HSCT at our institute, and in 75 (63 male, 12 female) of those patients, the basal condition was a non-malignant disease or another related disease. We excluded 51 subjects who died during the observation; they had been transferred to other hospitals and discontinued visiting our hospital. Twenty-four subjects were regularly followed up at our institute for at least 2 yr. One patient was excluded because of his age at HSCT (\> 20 yr old). Further, 23 patients (19 male, 4 female) were deemed to be eligible for the present study ([Table 1](#tbl_001){ref-type="table"}Table 1.Clinical profiles of the subjects in this study).

The age of the subjects ranged from 2--43 yr, and their age at HSCT ranged from 3 mo--19 yr (median: 3 yr old). The underlying non-malignant diseases of the patients were as follows: severe combined immunodeficiency (SCID) (n = 4), severe congenital neutropenia (SCN) (n = 3), Wiskott-Aldrich Syndrome (WAS) (n = 4), X-linked hyper IgM syndrome (XHIM) (n = 4), aplastic anemia (AA) (n = 3), ectodermal dysplasia with immunodeficiency (EAD-ID) (n = 2), chronic mucocutaneous candidiasis (CMC) (n = 1), PIK3CD mutation (PIK3CD) (n = 1), and hemophagocytic syndrome (HPS) (n = 1) ([Table 1](#tbl_001){ref-type="table"}).

We regularly checked the presence of chronic graft-versus-host disease (cGVHD), anthropometric data of height and weight, and blood pressure, and examined the endocrinological profiles and glucose and lipid metabolic profiles, i.e., thyroid function (TSH, fT3, fT4, and Tg), adrenal function (ACTH, cortisol, DHEA-S), gonadal function (LH, FSH, and testosterone or estradiol), IGF-1, PRL, HbA1c, fasting plasma glucose, T-chol, TG, and LDL cholesterol. The criteria for hypogonadism in our present study were as follows: a serum testosterone level of less than 3 ng/ml in men over the age of 14 or a basal serum FSH level of more than 8 IU/l in women of all ages.

In the present study, when the conditioning therapy included at least one of the following protocols: 1) TBI exceeding 5 Gy at once or 8 Gy via divided irradiation, 2) busulfan dose exceeding 9 mg/kg in total, and 3) L-PAM dose exceeding 140 mg/m^2^ in total, we defined the regimen as an myelo-ablative conditioning (MAC) regimen. Other conditioning regimens were considered reduced-intensity conditioning (RIC) regimens.

For GVHD, we used a standardized protocol of glucocorticoid therapy. First, 1 mg/kg/d of prednisolone was administered to initiate the therapy. The dosage was increased to up to 2 mg/kg/d if necessary. When the symptoms and/or signs of GVHD were attenuated, we discontinued the treatment after reducing the dosage by 10% every week.

For statistical analysis, we used the JMP13 software (SAS institute Inc.). For assessing the relationship between the risk factors (non-contiguous data) and contiguous data, Wilcoxon analysis was performed ([Fig. 1a, c, and d](#fig_001){ref-type="fig"}Fig. 1.(a) Box and whisker plot of glucocorticoid treatment durations after hematopoietic stem cell transplantation (HSCT) among patients from the two groups with or without cGVHD. The median of each group is indicated with a bold horizontal line in the boxes. The values in the boxes range from the lower quartile to the upper quartile. The data were statistically analyzed using the Mann-Whitney U test. \*\* *p*-value \< 0.01, \* *p*-value \< 0.05, N.S.: not significant. (b) Duration of glucocorticoid administration and ΔHtSDS were significantly correlated, as determined by the Pearson correlation coefficient (R = --0.62, *p*-value = 0.005). The ΔHtSDS was calculated by the formula ΔHtSDS = post-HSCT height SDS -- pre-HSCT height SDS (c) The ΔHtSDS in subjects conditioned with the myelo-ablative conditioning (MAC) regimen was significantly lower than that of subjects conditioned with the reduced-intensity conditioning (RIC) regimen. The data were analyzed using the Mann-Whitney U test. \*\* *p*-value \< 0.01, \* *p*-value \< 0.05, N.S.: not significant. (d) No significant difference was observed between the durations of glucocorticoid treatment in patients from the two groups conditioned using the RIC or MAC regimens. The data were obtained using the Mann-Whitney U test. \*\* *p*-value \< 0.01, \* *p*-value \< 0.05, N.S.: not significant.). For comparing the differences between two sets of contiguous data, we performed Pearson's correlation analysis ([Fig. 1b](#fig_001){ref-type="fig"}). In the multiple linear regression analysis shown in [Table 2](#tbl_002){ref-type="table"}Table 2.Results of the multiple linear regression analysis, *p* values less than 0.05 were considered statistically significant.

Results {#s3}
=======

Most subjects were male
-----------------------

X-liked congenital diseases, such as SCID, WAS, and XHIM, were major causes that necessitated HSCT; therefore, 19 out of 23 patients in our study were men. Most of the conditioning regimens (18/21; 86%) were based on the use of alkylating antineoplastic agents, since this is the most commonly used regimen in both reduced-intensity and myeloablative transplant procedures for treating immune-deficiency. The RIC regimen was used for nine patients (\#1, \#2, \#4, \#5, \#6, \#16, \#18, \#21, and \#22). There were no patients whose data suggested hypothyroidism, adrenal insufficiency, diabetes mellitus, and GH deficiency. Two patients (\#20 and \#22) developed hypercholesterolemia, requiring treatment with antihyperlipidemic agents.

The potential risk of MAC for growth retardation
------------------------------------------------

The thyroid function and the serum level of IGF-1 of the patients were within the normal range for their age and sex, suggesting that the growth retardation observed in our subjects was due to factors other than endocrinopathy. The durations of the glucocorticoid therapy for the subjects with cGVHD were significantly longer than those for subjects without cGVHD ([Fig. 1a](#fig_001){ref-type="fig"}) and negatively associated with the changes in height standard deviation score (ΔHtSDS) (R = --0.62, *p*-value = 0.005) ([Fig. 1b](#fig_001){ref-type="fig"}), suggesting that prolonged glucocorticoid therapy is a risk for growth retardation. Compared to the subjects treated with the RIC regimen, the ΔHtSDS was significantly reduced in those treated with the MAC regimen ([Fig. 1c](#fig_001){ref-type="fig"}, *p*-value = 0.012), suggesting the MAC regimen may be a potential risk for reducing the ΔHtSDS after HSCT. In the MAC treatment group, two subjects received prolonged glucocorticoid therapy for more than two years. However, even after excluding these two subjects from the analysis, a significant difference in the ΔHtSDS was obtained (data not shown). Furthermore, we observed no significant difference between the durations of glucocorticoid therapy in the patients subjected to the two conditioning regimens (RIC and MAC) ([Fig. 1d](#fig_001){ref-type="fig"}). These data suggest that in addition to prolonged glucocorticoid therapy, the MAC regimen is a factor that affects the growth of patients after HSCT.

To examine whether the duration of the glucocorticoid therapy and the conditioning regimen are independently associated with the growth retardation observed after HSCT, we performed a multiple linear regression analysis ([Table 2](#tbl_002){ref-type="table"}), which revealed that these two factors are independent predictors of ΔHtSDS after HSCT.

High prevalence of primary gonadal failure in female subjects
-------------------------------------------------------------

The serum levels of testosterone were examined in seven post-pubertal male subjects (\#8, \#13--\#17, and \#20), and no abnormal findings were identified. In contrast, all post-pubertal female patients (4/4; \#7, \#18, \#21, and \#23) developed hypergonadotropic hypogonadism, requiring hormone replacement therapy (HRT) ([Table 3](#tbl_003){ref-type="table"}Table 3.Profiles of female subjects with gonadal failure). The conditioning regimens for all female patients were based on the use of alkylating antineoplastic agents, which are toxic to ovarian tissues; two out of four female patients (\#18 and \#21) were treated with the RIC regimen. Except in the case for patient \#18, whose endocrinological data were obtained after the introduction of HRT, the profiles for all other patients suggested that the female patients developed primary ovarian failure, with markedly elevated gonadotropin levels and reduced anti-Müllerian hormone (AMH) and estradiol (E2) levels.

Discussion {#s4}
==========

Our study revealed two clinical points. First, the reduction of the ΔHtSDS is a possible complication of HSCT, and is caused by prolonged glucocorticoid therapy for cGVHD and the MAC regimen, independently. Second, gonadal failure is highly prevalent among female patients after HSCT. Therefore, this necessitates the need for HRT to induce pubertal development.

As observed after HSCT for malignant diseases ([@r8],[@r9],[@r10],[@r11],[@r12],[@r13],[@r14],[@r15]), our study revealed that the intensity of the conditioning regimen affects the growth of patients with non-malignant diseases after HSCT. Due to the limited number of the subjects, precise analyses were not performed; however, we speculate that TBI and chemotherapy, including CY or the combination of BU and CY, could affect growth in a dose-dependent manner. For elucidating the details of the pathophysiology of growth retardation without endocrine disorders after HSCT, an accumulation of cases is essential.

Our study revealed that primary ovarian failure would be a major complication after pediatric HSCT for non-malignant diseases. Alkylating agents, including busulfan, have been reported to impair the ovarian follicles ([@r16],[@r17],[@r18],[@r19]), and the recovery of gonadal function has been reported to be extremely rare ([@r9], [@r18]). Although the RIC regimen was used for patients \#18 and \#21 in our study, both patients developed ovarian failure, suggesting that even reduced dosages of alkylating agents would still have severe toxicity to the ovaries. The age at which the patients with ovarian failure underwent HSCT ranged from 1--14 yr old, suggesting that the toxicity of alkylating agents could affect the ovaries at any age.

Unlike the case in male patients, the high prevalence of gonadal failure in the female subjects is explained by the different mechanisms underlying the development of the ovaries and testes. In the ovaries, the follicular structures, including oocytes, are essential for the differentiation and maintenance of the granulosa and theca cells, which are the steroidogenic cells in the ovaries. Therefore, oocyte depletion due to alkylating agents subsequently causes the loss of steroidogenic cells, resulting in primary ovarian failure. In contrast, Leydig cells, the steroidogenic cells in the testes, are viable without the presence of germ cells. Therefore, androgen synthesis in male patients is maintained even after the depletion of germ cells caused by the exposure to alkylating agents.

The above findings show that the normal synthesis of androgen does not indicate the presence of germ cells in the testes, i.e., even developing secondary sexual characteristics, future fertility of the male subjects is not warranted. Indeed, in patients \#13, \#14, and \#17, the serum levels of FSH were higher than the normal range, and we cannot exclude the possibilities that these subjects will show impaired spermatogenesis in the future. It has been reported that the administration of alkylating agents seems to involve a higher risk of infertility in males than in females ([@r20]). Although the ultimate effect of busulfan on male fertility is currently not known, careful evaluation of reproductive prognosis in male and female patients is essential.

Even after conditioning using the RIC regimen, fertility preservation would be beneficial for all pediatric patients before HSCT. However, most patients with non-malignant diseases receive HSCT before they attain the reproductive age, resulting in limited options for the preservation of fertility, such as the cryopreservation of gonadal tissues. However, at present, cryopreservation of gonadal tissues is considered an experimental technique ([@r21], [@r22]), and this procedure may only be utilized for carefully selected patients as an experimental protocol.

Study Limitations {#s5}
=================

Our present study is based on a small number of the subjects, retrospective analysis, and short-term observations; additionally, careful interpretation of the data is required. However, our study revealed that HSCT for non-malignant patients, even those conditioned with RIC regimens, potentially caused late effects, especially hypogonadism in female patients. To further clarify the details of these late effects, studies involving a large number of cases are essential.

Conclusion {#s6}
==========

In conclusion, our study revealed the high prevalence of ovarian failure and growth retardation due to long-term glucocorticoid therapy after HSCT and treatment with the MAC regimen for non-malignant diseases. In addition to HSCT for malignant and related diseases, the pediatric patients receiving HSCT for non-malignant diseases should be followed up carefully, and careful consideration for preserving fertility before HSCT is essential.
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